Neuroendocrine Tumours
9
0
0
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
33.3%
3 terminated out of 9 trials
66.7%
-19.8% vs benchmark
11%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Open-Label Surufatinib in European Patients With NET
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Somatuline Predictive Factors in Acromegaly and NET
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours